Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study

Inclusion Criteria: * Men and women age \>18 years * Able to provide informed consent * A documented recent ACS event (i.e., defined as up to 14 days post-discharge from an index hospitalization for a non-ST-elevation MI \[NSTEMI\] or ST-elevation MI \[STEMI\] necessitating urgent and/or emergent percutaneous coronary intervention \[PCI\] and/or coronary after bypass graft \[CABG\]) * At least 6 months of continuous health plan membership and prescription drug benefit prior to enrollment * A registered e-mail address with Kaiser Permanente in order to obtain electronic consent (eConsent) for study participation Exclusion Criteria: * Receipt of BA/E on or within 3 months before the day of enrollment * A history of hypersensitivity to BA/E * Women who are pregnant or planning to become pregnant and/or breastfeeding mothers * A diagnosis of gout and/or previously known laboratory-confirmed hyperuricemia (serum uric acid \>8.0 mg/dL) * A history of tendon disorders or tendon rupture * Current and/or planned treatment with simvastatin/pravastatin, cyclosporine, fibrates, and/or bile acid sequestrants (to avoid drug-drug interactions) * A known life-limiting diagnosis (e.g., stage D heart failure, severe liver disease, end-stage kidney disease \[ESKD\] requiring chronic dialysis or an estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2, metastatic cancer and/or actively receiving systemic chemotherapy) * Institutionalized and/or receiving palliative care * Non-English speaking